Stellar Biotechnologies, Inc. (47) | License Agreements (8)
Recent Contracts
-
Third Amendment to Exclusive License Agreement, dated October 26, 2022, by and between the Registrant and Yissum Research Development Company
(Filed With SEC on December 16, 2022)
-
Exclusive License Agreement, dated as of March 16, 2021, by and between the Edesa Biotech Research, Inc. andDr. Saul Yedgar
(Filed With SEC on March 22, 2021)
-
License Agreement by and between Edesa Biotech Research, Inc. and NovImmune SA dated April 17, 2020
(Filed With SEC on April 23, 2020)
-
Exclusive License Agreement, dated as of June 29, 2016, by and between the Registrant and Yissum Research Development Company
(Filed With SEC on August 30, 2019)
-
First Amendment to Exclusive License Agreement, dated April 3, 2017, by and between the Registrant and Yissum Research Development Company
(Filed With SEC on August 30, 2019)
-
Second Amendment to Exclusive License Agreement, dated May 7, 2017, by and between the Registrant and Yissum Research Development Company
(Filed With SEC on August 30, 2019)
-
Exclusive License Agreement, dated as of June 15, 2016, by and between the Registrant and Cipher Pharmaceuticals Inc
(Filed With SEC on August 30, 2019)
-
License and Development Agreement, dated as of August 27, 2017, by and between the Registrant and Pendopharm, a division of Pharmascience Inc
(Filed With SEC on August 30, 2019)
